关注
Gabriel Léger
Gabriel Léger
在 ucsd.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Alzheimer's disease
JAS Lopez, HM González, GC Léger
Handbook of clinical neurology 167, 231-255, 2019
7012019
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia
M Mesulam, A Wicklund, N Johnson, E Rogalski, GC Léger, A Rademaker, ...
Annals of Neurology: Official Journal of the American Neurological …, 2008
5812008
Dopa decarboxylase activity of the living human brain.
A Gjedde, J Reith, S Dyve, G Leger, M Guttman, M Diksic, A Evans, ...
Proceedings of the National Academy of Sciences 88 (7), 2721-2725, 1991
2031991
Pharmacological treatment of Alzheimer disease
F Massoud, GC Léger
The Canadian Journal of Psychiatry 56 (10), 579-588, 2011
1482011
Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to …
H Kuwabara, P Cumming, J Reith, G Leger, M Diksic, AC Evans, ...
Journal of Cerebral Blood Flow & Metabolism 13 (1), 43-56, 1993
1241993
6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods
H Hoshi, H Kuwabara, G Léger, P Cumming, M Guttman, A Gjedde
Journal of Cerebral Blood Flow & Metabolism 13 (1), 57-69, 1993
1191993
Striatal L‐dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis
A Gjedde, GC Léger, P Cumming, Y Yasuhara, AC Evans, M Guttman, ...
Journal of neurochemistry 61 (4), 1538-1541, 1993
921993
Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans
P Cumming, GC Léger, H Kuwabara, A Gjedde
Journal of Cerebral Blood Flow & Metabolism 13 (4), 668-675, 1993
911993
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3 …
DK Burns, RC Alexander, KA Welsh-Bohmer, M Culp, C Chiang, J O’Neil, ...
The Lancet Neurology 20 (7), 537-547, 2021
712021
Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease
H Kuwabara, P Cumming, Y Yasuhara, GC Léger, M Guttman, M Diksic, ...
Journal of Nuclear Medicine 36 (7), 1226-1231, 1995
601995
Comparing the electronic and standard versions of the Montreal Cognitive Assessment in an outpatient memory disorders clinic: a validation study
JL Berg, J Durant, GC Léger, JL Cummings, Z Nasreddine, JB Miller
Journal of Alzheimer's Disease 62 (1), 93-97, 2018
572018
Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia
GC Léger, SJ Banks
Dementia and geriatric cognitive disorders 37 (1-2), 104-112, 2014
532014
Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa
M Guttman, G Leger, A Reches, A Evans, H Kuwabara, JM Cedarbaum, ...
Movement disorders: official journal of the Movement Disorder Society 8 (3 …, 1993
521993
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
M Guttman, G Léger, JM Cedarbaum, A Reches, W Woodward, A Evans, ...
Annals of Neurology: Official Journal of the American Neurological …, 1992
481992
Correction for partial volume effects in PET using MRI-based 3-D simulations of individual human brain metabolism
OG Rousset, Y Ma, GC Léger, AH Gjedde, AC Evans
Annals of Nuclear Medicine 7 (SUPPL. 1), S31-S32, 1993
461993
Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson …
JM Cedarbaum, G Leger, M Guttman
Clinical neuropharmacology 14 (4), 330-342, 1991
461991
Structural and functional MRI differences in master sommeliers: a pilot study on expertise in the brain
SJ Banks, KR Sreenivasan, DM Weintraub, D Baldock, M Noback, ...
Frontiers in Human Neuroscience 10, 414, 2016
422016
Toward a revision of criteria for the dementias
K Rockwood, RW Bouchard, R Camicioli, G Léger
Alzheimer's & Dementia 3 (4), 428-440, 2007
392007
Relationship between the activities of daily living questionnaire and the montreal cognitive assessment
J Durant, GC Leger, SJ Banks, JB Miller
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 4, 43-46, 2016
382016
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders
TF Gendron, MG Heckman, LJ White, AM Veire, O Pedraza, AR Burch, ...
Cell Reports Medicine 3 (4), 2022
342022
系统目前无法执行此操作,请稍后再试。
文章 1–20